Prior Antiplatelet Therapy, Excluding Phosphodiesterase Inhibitor Is Associated with Poor Outcome in Patients with Spontaneous Intracerebral Haemorrhage
- 51 Downloads
There is conflicting results on whether prior antiplatelet therapy (APT) is associated with poor outcome in spontaneous intracerebral haemorrhage (ICH) patients. To determine whether prior APT is associated with spontaneous ICH, and whether there is a difference between the different types of APT, including cyclooxygenase inhibitor (COX-I), adenosine diphosphate receptor inhibitor (ADP-I) and phosphodiesterase inhibitor (PDE-I). A retrospective study of patients with ICH diagnosed between 2001 and 2013 in the National Health Insurance Research Database. Baseline unbalance between APT and non-APT groups was solved by multivariable adjustment (primary analysis) and propensity score matching (sensitivity analysis). Patients with prior APT had a higher rate of in-hospital death (odds ratio [OR], 1.16; 95% confidence interval [CI], 1.09–1.23) compared to non-APT group. Compared to non-APT group, there was a greater rate of in-hospital death with spontaneous ICH with ADP-I (OR, 1.49; 95% CI, 1.24–1.79) and COX-I (OR, 1.17; 95% CI, 1.09–1.25). PDE-I exhibited no difference in in-hospital death with spontaneous ICH (OR, 1.03; 95% CI, 0.91–1.16) compared to non-APT group. Remarkably, the in-hospital mortality rate was significantly higher in the ADP-I group than in the PDE-I group (hazard ratio, 1.45; 95% CI, 1.17–1.80). In this study, ADP-I and COX-1, but not PDE-I, are the most likely contributors to the association of APT with poor outcome with spontaneous ICH patients. These findings suggest that the complexity of the different mechanism of actions of prior APT can alter the outcome in spontaneous ICH.
KeywordsIntracerebral haemorrhage Antiplatelet treatment In-hospital mortality Outcome
The authors thank for Alfred Hsing-Fen Lin and Zoe Ya-Jhu Syu for their statistical assistance.
PSM propensity score matching
ICH intracerebral haemorrhage
ADP-I adenosine diphosphate receptor inhibitor
COX-I irreversible cyclooxygenase inhibitor
PDE-I phosphodiesterase inhibitor
This work was supported by the Chang Gung Memorial Hospital (CMRPG3H1061, CMRPG3G1002) grant number.
Compliance with Ethical Standards
This study was exempt from approval requirements by the Institutional Review Board of Chang Gung Memorial Hospital in Taiwan (IRB number, 201601518B0) and without permission of patient’s consent, given that it was an epidemiology study with no definable patient information.
Conflict of Interest
The authors declare that they have no conflict of interests.
- 1.Naidech AM, Bassin SL, Bernstein RA, Batjer HH, Alberts MJ, Lindholm PF, et al. Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage. Neurocrit Care. 2009;11(3):307–10. https://doi.org/10.1007/s12028-009-9219-7.CrossRefPubMedGoogle Scholar
- 3.Joseph B, Pandit V, Aziz H, Kulvatunyou N, Hashmi A, Tang A, et al. Clinical outcomes in traumatic brain injury patients on preinjury clopidogrel: a prospective analysis. The journal of trauma and acute care surgery. 2014;76(3):817–20. https://doi.org/10.1097/TA.0b013e3182aafcf0.CrossRefPubMedGoogle Scholar
- 4.Roquer J, Rodriguez Campello A, Gomis M, Ois A, Puente V, Munteis E. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005;252(4):412–6. https://doi.org/10.1007/s00415-005-0659-5.CrossRefPubMedGoogle Scholar
- 6.Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009;72(16):1397–402. https://doi.org/10.1212/01.wnl.0000342709.31341.88.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Toyoda K, Okada Y, Minematsu K, Kamouchi M, Fujimoto S, Ibayashi S, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005;65(7):1000–4. https://doi.org/10.1212/01.wnl.0000179178.37713.69.CrossRefPubMedGoogle Scholar
- 15.Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37(1):129–33. https://doi.org/10.1161/01.STR.0000196991.03618.31.CrossRefPubMedGoogle Scholar
- 19.Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11. https://doi.org/10.1016/j.atherosclerosissup.2005.09.002.CrossRefPubMedGoogle Scholar
- 20.Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005;36(1):74–9. https://doi.org/10.1161/01.STR.0000149628.80251.b8.CrossRefPubMedGoogle Scholar
- 21.Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7. https://doi.org/10.1016/S0140-6736(04)16721-4.CrossRefPubMedGoogle Scholar
- 22.Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. The Lancet Neurology. 2010;9(10):959–68. https://doi.org/10.1016/S1474-4422(10)70198-8.CrossRefPubMedGoogle Scholar
- 23.Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, et al. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. The Lancet Neurology. 2018;17(6):509–18. https://doi.org/10.1016/S1474-4422(18)30128-5.CrossRefPubMedGoogle Scholar
- 28.Le Manach Y, Kahn D, Bachelot-Loza C, Le Sache F, Smadja DM, Remones V, et al. Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. PLoS One. 2014;9(8):e104491. https://doi.org/10.1371/journal.pone.0104491.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Kelly RP, Close SL, Farid NA, Winters KJ, Shen L, Natanegara F, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol. 2012;73(1):93–105. https://doi.org/10.1111/j.1365-2125.2011.04049.x.CrossRefPubMedPubMedCentralGoogle Scholar